is fluvoxamine fda approved for ocd in adults and children eight and older?
“It's approved for adults and for children eight and older.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-10-03, at 01:32. hear it in context →
the episode: SSRI Dosing for OCD: Beyond FDA Guidelines (at 01:32). we link the show's own page; we do not re-host audio.
first, the part that holds
this one holds up. the current FDA label for fluvoxamine immediate-release tablets lists OCD as the indication and gives dosing for adults and for children and adolescents aged 8 to 17.
what we found when we went and looked
we read the current DailyMed label for fluvoxamine maleate tablets (updated 2026-09-11). it lists one indication, obsessions and compulsions in OCD. it gives a pediatric dosing schedule for ages 8 to 17 (start at 25 mg at bedtime, maximum 200 mg/day for ages 8 to 11 and 300 mg/day for ages 12 to 17), and it bases pediatric efficacy on a 10-week controlled trial in patients aged 8 to 17. the boxed warning says the tablets are "not approved for use in pediatric patients except those with obsessive compulsive disorder." there is one formulation caveat the quote doesn't cover: the extended-release capsule label says those capsules "have not been evaluated in pediatric patients," so the age-8 claim belongs to the immediate-release tablets.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| fluvoxamine is FDA approved for OCD in adults | confirmed | both the immediate-release tablet label and the extended-release capsule label list OCD as the indication, with adult dosing and adult efficacy trials. the original application was approved 1994-12-05 (NDA 020243, now discontinued; generics remain on the market). [1][2][3] |
| fluvoxamine is FDA approved for OCD in children aged eight and older | confirmed | the tablet label gives pediatric dosing for ages 8 to 17, cites a 10-week controlled pediatric trial in ages 8 to 17, and its boxed warning says the tablets are not approved in pediatric patients except those with OCD. the label covers ages 8 to 17. 'eight and older' is right, since adult approval starts at 18. Drugs@FDA lists a 1997-03-25 supplement labeled 'efficacy-new patient population'. that page doesn't say which population, so we don't rely on it for the pediatric date. [1][3] |
| the pediatric approval applies to every fluvoxamine formulation | overstated | the extended-release capsule label (revised 5/2025) says the capsules 'have not been evaluated in pediatric patients'. it notes that the lowest available capsule dose may not suit pediatric patients who haven't taken fluvoxamine before. pediatric evidence comes from the immediate-release tablets only. the speaker didn't make this broader claim. it's a reading listeners could take away from the quote. [2] |
| OCD is the only pediatric indication for fluvoxamine | confirmed | OCD is fluvoxamine's only labeled indication at any age. the labels state that safety and effectiveness in pediatric patients other than those with OCD have not been established. [1][2] |
both directions
for the speaker: the current tablet label, updated 2026-09-11, gives the OCD indication, dosing for ages 8 to 17 with age-banded maximums, and a 10-week controlled pediatric trial in ages 8 to 17. its boxed warning also names OCD as the only pediatric use the tablets are approved for. the extended-release capsule label likewise lists OCD in adults.
against: nothing in the record contradicts the claim as spoken. it is only incomplete in one place. the extended-release capsules were never evaluated in children, so the pediatric approval covers the immediate-release tablets and not the drug in every form. the record also shows OCD is fluvoxamine's only labeled indication, so the approval should not be read as covering pediatric depression or anxiety, even though fluvoxamine is used off-label for those.
what this cannot say
labels confirm what the FDA approved. they don't say how strong the pediatric evidence is beyond one 10-week trial, how well the drug works compared with other OCD treatments, or how it performs over the long term in children. the labels note that long-term effects on growth and development haven't been studied. the Drugs@FDA overview we read doesn't spell out what the 1997 'new patient population' supplement covered, so we don't give a pediatric approval date. we read generic labels on DailyMed. their wording matches the reference product's but may lag behind the latest revisions to it.
sources, each one fetched and read
- DailyMed, fluvoxamine maleate tablet, prescribing information (updated 2026-09-11) What we read there: indicated for 'treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD)'; boxed warning: 'not approved for use in pediatric patients except those with obsessive compulsive disorder'; pediatric dosing ages 8-17, starting at 25 mg at bedtime, maximum 200 mg/day (ages 8-11) and 300 mg/day (ages 12-17); 10-week controlled trial in pediatric patients ages 8 to 17. Fetched 2026-10-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eeb14df-6fcf-a737-5359-5744eb4accea
- DailyMed, fluvoxamine maleate extended-release capsules, prescribing information (revised 5/2025) What we read there: 'Fluvoxamine maleate extended-release capsules have not been evaluated in pediatric patients'; 'Safety and effectiveness in the pediatric population other than pediatric patients with OCD have not been established.' Fetched 2026-10-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4527a684-51c0-1858-e063-6394a90a2631&type=display
- FDA, Drugs@FDA, NDA 020243 (fluvoxamine maleate) overview What we read there: original approval 1994-12-05; supplement 6 approved 1997-03-25, labeled 'Efficacy-New Patient Population'; marketing status discontinued. Fetched 2026-10-14 (HTTP 200). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020243
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam